ResMed (NYSE:RMD) is a company that has been recognized for changing lives with its award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases.
The company is known as a global leader, servicing over 100 countries in connected care, with more than 3 million patients remotely monitored every day. With a team numbering more than 5,000 people, ResMed has shown its commitment to creating tech-driven medical devices that improve quality of life, reduce the impact of chronic disease, all while saving healthcare costs. The company has manufacturing facilities in Australia, France, Singapore and the U.S. and achieved revenues of $1.7 billion USD in fiscal year 2014–15.
When creating its products, ResMed had the ultimate goal in mind to improve the quality of life for patients, prevent progression of chronic diseases, and reduce overall healthcare system costs.
Founded in 1989, the company’s first steps were toward commercializing a device for treating obstructive sleep apnea (OSA), a major subset of sleep-disordered breathing (SDB).
For those interested in obtaining a ResMed product, the company does offer a non-contact sleep monitor for the general public. It is called the S+ and it is currently available in the US.
With the continual development of their products, ResMed is helping to spread awareness of the prevalence of sleep-disordered breathing (SDB) and its major manifestation, obstructive sleep apnea (OSA), since more than 80% of cases are believed to be undiagnosed. As more than 70% of people with obesity, heart failure, type 2 diabetes and drug-resistant hypertension have some form of sleep-disordered breathing, ResMed is a company that recognizes this and provides solutions in response.
For more on ResMed, visit the company’s website.